{"id":"exenatide-placebo-saline","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Exenatide placebo saline is an inert control formulation used in clinical trials to compare against the active GLP-1 receptor agonist exenatide. It contains no active drug and serves as a comparator to establish the efficacy and safety profile of exenatide in randomized controlled studies.","oneSentence":"This is a placebo (saline injection) with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:29:55.640Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in clinical trials of exenatide for type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07497399","phase":"PHASE2","title":"Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-04","conditions":"Multiple Sclerosis","enrollment":120},{"nctId":"NCT05610800","phase":"PHASE2","title":"Exenatide for Smoking Cessation and Prevention of Weight Gain","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-12-07","conditions":"Smoking Cessation, Weight Gain","enrollment":140},{"nctId":"NCT06252623","phase":"PHASE1","title":"Exenatide For Reducing the Reinforcing Effects of Cocaine","status":"WITHDRAWN","sponsor":"Christopher D. Verrico","startDate":"2024-08-01","conditions":"Cocaine Use Disorder","enrollment":""},{"nctId":"NCT04897802","phase":"PHASE4","title":"Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2021-09-13","conditions":"Hypopituitarism, Central Diabetes Insipidus, Panhypopituitarism","enrollment":42},{"nctId":"NCT04154072","phase":"PHASE2","title":"A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease","status":"COMPLETED","sponsor":"Neuraly, Inc.","startDate":"2020-02-27","conditions":"Parkinson Disease","enrollment":255},{"nctId":"NCT02673931","phase":"NA","title":"GLP-1 and Hyperoxia for Organ Protection in Heart Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2016-02","conditions":"Coronary Disease, Shock, Cardiogenic, Renal Failure","enrollment":1400},{"nctId":"NCT04909333","phase":"NA","title":"Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-04-29","conditions":"Endogenous Hyperinsulinism","enrollment":29},{"nctId":"NCT03835013","phase":"NA","title":"Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2019-02-11","conditions":"Cardiovascular Diseases","enrollment":26},{"nctId":"NCT02829502","phase":"PHASE2","title":"The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke","status":"UNKNOWN","sponsor":"Christina Kruuse","startDate":"2016-08","conditions":"Ischemic Stroke","enrollment":30},{"nctId":"NCT01154933","phase":"PHASE2","title":"Exeantide in Type 2 Diabetes on Insulin","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":24},{"nctId":"NCT00882050","phase":"PHASE1, PHASE2","title":"Intravenous Exenatide (Byetta) During Surgery","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2009-03","conditions":"Euglycemia, Hypoglycemia, Hyperglycemia","enrollment":104},{"nctId":"NCT03232112","phase":"PHASE2","title":"Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?","status":"COMPLETED","sponsor":"Anders Fink-Jensen, MD, DMSci","startDate":"2017-08-07","conditions":"Alcohol Dependence, in Remission, Addiction, Alcohol","enrollment":152},{"nctId":"NCT04159766","phase":"PHASE2","title":"A Study With NLY01 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Neuraly, Inc.","startDate":"2019-10-16","conditions":"Type2 Diabetes, Diabetes Mellitus, Type 2","enrollment":20},{"nctId":"NCT02975297","phase":"PHASE1, PHASE2","title":"Exenatide Once Weekly for Smoking Cessation","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2016-07","conditions":"Smoking Cessation","enrollment":84},{"nctId":"NCT02802514","phase":"PHASE4","title":"A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2016-09-20","conditions":"Diabetes Mellitus","enrollment":5},{"nctId":"NCT02690987","phase":"EARLY_PHASE1","title":"Gut Hormones in Obesity, Nicotine and Alcohol Dependence","status":"UNKNOWN","sponsor":"Imperial College London","startDate":"2015-08","conditions":"Obesity, Smoking Cessation, Alcoholism","enrollment":95},{"nctId":"NCT03672604","phase":"PHASE1","title":"A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects","status":"COMPLETED","sponsor":"Neuraly, Inc.","startDate":"2018-09-19","conditions":"Safety and Tolerability in Healthy Volunteers","enrollment":96},{"nctId":"NCT02104739","phase":"PHASE4","title":"Effects of Antidiabetic Medications on the Postprandial State in Prediabetes","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2014-04","conditions":"Prediabetes, Obesity","enrollment":21},{"nctId":"NCT02442791","phase":"NA","title":"GLP-1 Analogs for Neuroprotection After Cardiac Arrest","status":"COMPLETED","sponsor":"Jesper Kjaergaard","startDate":"2014-06","conditions":"Cardiac Arrest, Coma","enrollment":120},{"nctId":"NCT01381926","phase":"PHASE4","title":"Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2011-02","conditions":"Type 2 Diabetes Mellitus, Bone Remodeling","enrollment":14},{"nctId":"NCT02541734","phase":"PHASE1, PHASE2","title":"Effect of Gelofusine on GLP1-receptor Imaging","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-08","conditions":"Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus","enrollment":12},{"nctId":"NCT02838589","phase":"PHASE2","title":"The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers","status":"COMPLETED","sponsor":"Christina Kruuse","startDate":"2016-08","conditions":"Stroke","enrollment":30},{"nctId":"NCT01744236","phase":"PHASE4","title":"SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2013-04","conditions":"Type 2 Diabetes","enrollment":70},{"nctId":"NCT01281228","phase":"NA","title":"The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2011-09","conditions":"Diabetes Mellitus, Diabetes Mellitus, Type 2, Obesity","enrollment":48},{"nctId":"NCT00835848","phase":"PHASE4","title":"Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2009-01","conditions":"Myocardial Infarction","enrollment":100},{"nctId":"NCT02059564","phase":"PHASE1","title":"A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2013-12","conditions":"Diabetes Mellitus","enrollment":44},{"nctId":"NCT01254123","phase":"PHASE3","title":"Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2009-11","conditions":"Patients With a First Acute Myocardial Infarction to be Treated With Primary Percutaneous Coronary Intervention (PCI).","enrollment":40},{"nctId":"NCT00744224","phase":"NA","title":"PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2009-02","conditions":"Glucocorticoid-induced Glucometabolic Abnormalities, Glucocorticoid-induced Beta-cell Dysfunction","enrollment":8},{"nctId":"NCT00974272","phase":"PHASE4","title":"Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation","status":"COMPLETED","sponsor":"Carl T. Hayden VA Medical Center","startDate":"2006-08","conditions":"Type 2 Diabetes Mellitus, Impaired Glucose Tolerance","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Exenatide placebo (saline)","genericName":"Exenatide placebo (saline)","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo (saline injection) with no active pharmacological mechanism. Used for Control arm in clinical trials of exenatide for type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}